E-LIB Suche - Ergebnisse für: Peer, Cody J

1

Tofacitinib to prevent anti-drug antibody formation against..:

Skorupan, Nebojsa ; Peer, Cody J. ; Zhang, Xianyu...
Frontiers in Oncology. 14 (2024) - p. , 2024

Link: https://doi.org/10.3389/..

2

Distinct uptake and elimination profiles for trastuzumab, h..:

Silvestri, Vanesa L ; Tran, Andy D ; Chung, Monika...
Neuro-Oncology. 26 (2024) 6 - p. 1067-1082 , 2024

Link: https://doi.org/10.1093/..

3

Pharmacogenomic Variation May Impact Cyclophosphamide Metab..:

Zeng, Yi ; Arisa, Oluwatobi ; Peer, Cody J....
Transplantation and Cellular Therapy. 30 (2024) 2 - p. S457 , 2024

Link: https://doi.org/10.1016/..

4

Baricitinib for Refractory Chronic Graft-Versus-Host Diseas..:

Holtzman, Noa G. ; Im, Dr. Annie P. ; Ostojic, Alen...
Transplantation and Cellular Therapy. 29 (2023) 2 - p. S251-S252 , 2023

Link: https://doi.org/10.1016/..

5

Preclinical Evaluation of the FGFR-Family Inhibitor Futibat..:

Wu, Jerry T. ; Cheuk, Adam ; Isanogle, Kristine...
Cancers. 15 (2023) 16 - p. 4034 , 2023

Link: https://doi.org/10.3390/..

6

In Silico Re‐Optimization of Atezolizumab Dosing Using Popu..:

Peer, Cody J. ; Schmidt, Keith T. ; Arisa, Oluwatobi...
The Journal of Clinical Pharmacology. 63 (2023) 6 - p. 672-680 , 2023

Link: https://doi.org/10.1002/..

7

First-in-human phase 1 clinical trial of anti-core 1 O-glyc..:

Cole, Christopher B. ; Morelli, Maria Pia ; Fantini, Massimo...
Journal of Experimental & Clinical Cancer Research. 42 (2023) 1 - p. , 2023

Link: https://doi.org/10.1186/..

8

POSTER: ABCL-187 Phase 2 Response-Adapted Study of Ibrutini..:

Simard, Jillian ; Phelan, James D ; Melani, Christopher...
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) - p. S205 , 2023

Link: https://doi.org/10.1016/..

9

ABCL-187 Phase 2 Response-Adapted Study of Ibrutinib With T..:

Simard, Jillian ; Phelan, James D ; Melani, Christopher...
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) - p. S424-S425 , 2023

Link: https://doi.org/10.1016/..

10

Glycemia and Gluconeogenesis With Metformin and Liraglutide..:

Dietsche, Katrina B ; Magge, Sheela N ; Dixon, Sydney A...
The Journal of Clinical Endocrinology & Metabolism. 109 (2023) 5 - p. 1361-1370 , 2023

Link: https://doi.org/10.1210/..

11

EXTH-56. CSF PENETRATION COMPARISON OF TWO ORAL FORMULATION..:

Cabanas, Natalia Corvalan ; McCully, Cynthia Lester ; Peer, Cody...
Neuro-Oncology. 25 (2023) Supplement_5 - p. v237-v237 , 2023

Link: https://doi.org/10.1093/..

12

Clinical protocol: Feasibility of evaluating abemaciclib ne..:

Nduom, Edjah K. ; Glod, John ; Brown, Desmond A....
PLOS ONE. 18 (2023) 9 - p. e0291068 , 2023

Link: https://doi.org/10.1371/..

13

Interventional pharmacoeconomics for immune checkpoint inhi..:

Wesevich, Austin ; Goldstein, Daniel A. ; Paydary, Koosha...
British Journal of Cancer. 129 (2023) 9 - p. 1389-1396 , 2023

Link: https://doi.org/10.1038/..

14

TRLS-02. FEASIBILITY OF EVALUATING ABEMACICLIB NEUROPHARMAC..:

Jackson, Sadhana ; Glod, John ; Peer, Cody...
Neuro-Oncology. 25 (2023) Supplement_1 - p. i79-i79 , 2023

Link: https://doi.org/10.1093/..

15

Phase I trial of panobinostat in children with diffuse intr..:

Monje, Michelle ; Cooney, Tabitha ; Glod, John...
Neuro-Oncology. 25 (2023) 12 - p. 2262-2272 , 2023

Link: https://doi.org/10.1093/..